JPRN-UMIN000013912已完成未知
Phase II study of bortezomib maintenance therapy for multiple myeloma patients - BOMB-after
ational Hospital Organization Disaster Medical Center of Japan0 个研究点目标入组 96 人开始时间: 2014年5月9日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 96
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 65years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •The exclusion criteria were a serum creatinine level2.05 mg/dL at time of high-dose therapy (HDT), liver dysfunction (e.g., a serum total bilirubin level2.0 mg/dL, or serum aspartate/alanine aminotransferase or alkaline phosphatase levels more than 2.5 times the upper limit of normal), grade 3 or worse peripheral neuropathy, significant comorbidity that would preclude ASCT, poor performance status (grade 3), and a history of any other malignancy with the exception of basal cell carcinoma and stage I cervical cancer
研究者
相似试验
进行中（未招募）
不适用
Randomized phase II study of bortezomib, lenalidomide and dexamethasone versus lenalidomide and dexamethasone in elderly patients with newly diagnosed multiplemyelomaKCT0004508Samsung Medical Center126
尚未招募
2 期
A pahse 2 study of bortezomib monotherapy for Epstein-Barr virus positive T or NK cell lymphoproliferative disease (Chronic active Epstein-Barr virus infection)Epstein-Barr virus positive T or NK cell lymphoproliferative disease (Chronic active Epstein-Barr virus infection)JPRN-UMIN000020315Tokyo Medical and Dental University1
已完成
不适用
Phase I study of weekly bortezomib for patients with recurrent or refractory multiple myelomaMultiple myelomaJPRN-UMIN000002922PO IB-HOPE12
已完成
2 期
A randomized phase 2 study of bortezomib, cyclophosphamide and dexamethasone induction (VCD) compared with VCD and daratumumab induction followed by daratumumab maintenance (VCDD) for the initial treatment of transplant ineligible patients with multiple myeloma.Cancer - MyelomaMultiple MyelomaACTRN12617000202369Alfred Health135
招募中
2 期
Phase II study of bortezomib-melphalan-prednisolone induction therapy followed by lenalidomide-plus-dexamethasone consolidation and lenalidomide maintenance for newly diagnosed patients with multiple myeloma ineligible for stem cell transplantation.Multiple myelomaJPRN-UMIN000009042Japan Myeloma Expert Network (J-MEN) of Japan Myeloma Network (JMN)80